 |
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells |
|---|---|
| Trade Name | |
| Orphan Indication | Chronic granulomatous disease |
| USA Market Approval | USA |
| USA Designation Date | 2001-11-01 00:00:00 |
| Sponsor | Nexell Therapeutics Inc.;9 Parker;Irvine, California, 92618 |
